SNAX vs HIMS vs NXRT

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -40. 9% for Stryve Foods, Inc. (SNAX). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 59. 2x trailing P/E, making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 0%, compared to -100. 0% for Stryve Foods, Inc. (SNAX). Over 10 years, the gap is even starker: HIMS returned +207. 9% versus SNAX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryve Foods, Inc.

(SNAX) is the lower-risk stock at -3. 16β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately -179% more volatile than SNAX relative to the S&P 500. On balance sheet safety, Hims & Hers Health, Inc. (HIMS) carries a lower debt/equity ratio of 2% versus 15% for Stryve Foods, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -40. 9% for Stryve Foods, Inc. (SNAX). On earnings-per-share growth, the picture is similar: Stryve Foods, Inc. grew EPS 47. 0% year-over-year, compared to -30. 8% for NexPoint Residential Trust, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -107. 5% for Stryve Foods, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NXRT leads at 11. 1% versus -87. 1% for SNAX. At the gross margin level — before operating expenses — NXRT leads at 84. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, NXRT (7.

7% yield) pays a dividend. SNAX, HIMS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryve Foods, Inc.

(SNAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -3. 16)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SNAX: -100. 0%, HIMS: +207. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNAX (Consumer Defensive) and HIMS (Healthcare) and NXRT (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SNAX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; NXRT is a small-cap income-oriented stock. NXRT pays a dividend while SNAX, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.